Research programme: red blood cell therapeutics - Rubius TherapeuticsAlternative Names: Red-Cell Therapeutic
Latest Information Update: 20 Jun 2016
At a glance
- Originator Rubius Therapeutics
- Class Cell therapies
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Phenylketonuria